AstraZeneca, Ionis plan to seek FDA approval for rare-disease therapy this year
U.S.-listed shares of AstraZeneca were up 2.5% in trading on Tuesday after the company said an experimental therapy for hereditary transthyretin-mediated amyloid polyneuropathy met its...